Buy Or Sell Opportunity • Jul 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.0% to €211. The fair value is estimated to be €268, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Buy Or Sell Opportunity • Jul 08
Now 21% undervalued Over the last 90 days, the stock has risen 3.6% to €222. The fair value is estimated to be €281, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Buy Or Sell Opportunity • May 08
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 10% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Reported Earnings • Apr 24
First quarter 2026 earnings released First quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Upcoming Dividend • Mar 20
Upcoming dividend of €0.74 per share Eligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (0.9%). Buy Or Sell Opportunity • Mar 02
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.4% to €232. The fair value is estimated to be €292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period. Reported Earnings • Feb 17
Full year 2025 earnings released Full year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe. Aankondiging • Feb 17
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time. Buy Or Sell Opportunity • Feb 09
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at €233. The fair value is estimated to be €295, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Declared Dividend • Feb 09
Dividend of €0.74 announced Dividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%. Aankondiging • Feb 07
Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026 Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026. Aankondiging • Feb 05
Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026 Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division. Aankondiging • Jan 28
Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026 Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026 Aankondiging • Jan 16
Sartorius Expands Bio-Circular Product Offering for More Sustainable Bioprocesses Sartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network. Buy Or Sell Opportunity • Jan 14
Now 21% undervalued Over the last 90 days, the stock has risen 11% to €254. The fair value is estimated to be €322, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Buy Or Sell Opportunity • Nov 14
Now 21% undervalued Over the last 90 days, the stock has risen 14% to €226. The fair value is estimated to be €287, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 27% per annum over the same time period. Reported Earnings • Oct 17
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Aankondiging • Oct 17
Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025 Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%. Reported Earnings • Jul 24
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. New Risk • Jul 04
New major risk - Revenue and earnings growth Earnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin). Buy Or Sell Opportunity • May 23
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to €217. The fair value is estimated to be €277, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Buy Or Sell Opportunity • May 07
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 12% to €226. The fair value is estimated to be €288, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Aankondiging • Apr 17
Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025 Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively. Reported Earnings • Apr 17
First quarter 2025 earnings released First quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Aankondiging • Mar 29
Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025 Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025. Buy Or Sell Opportunity • Mar 26
Now 24% undervalued Over the last 90 days, the stock has risen 1.9% to €219. The fair value is estimated to be €290, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Upcoming Dividend • Mar 21
Upcoming dividend of €0.74 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 01 April 2025. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (0.7%). Buy Or Sell Opportunity • Mar 04
Now 23% undervalued Over the last 90 days, the stock has risen 3.3% to €222. The fair value is estimated to be €287, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period. New Risk • Feb 19
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.5% net profit margin). Aankondiging • Feb 18
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025. Reported Earnings • Feb 17
Full year 2024 earnings released: EPS: €1.21 (vs €3.00 in FY 2023) Full year 2024 results: EPS: €1.21 (down from €3.00 in FY 2023). Revenue: €3.38b (flat on FY 2023). Net income: €84.0m (down 59% from FY 2023). Profit margin: 2.5% (down from 6.0% in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Declared Dividend • Feb 17
Dividend of €0.74 announced Dividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 65%. Cash payout ratio: 11%. Aankondiging • Feb 09
Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025 The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025. Buy Or Sell Opportunity • Jan 16
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to €233. The fair value is estimated to be €291, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 30% per annum over the same time period. Buy Or Sell Opportunity • Dec 16
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.9% to €223. The fair value is estimated to be €286, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings are also forecast to grow by 36% per annum over the same time period. Aankondiging • Nov 16
Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025 Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025 Buy Or Sell Opportunity • Nov 15
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to €213. The fair value is estimated to be €276, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings are also forecast to grow by 37% per annum over the same time period. Reported Earnings • Oct 18
Third quarter 2024 earnings released Third quarter 2024 results: EPS: €0.21. Revenue: €793.6m (down 2.1% from 3Q 2023). Net income: €14.2m (up 65% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Aankondiging • Sep 19
Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3). Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin.
Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Reported Earnings • Jul 20
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: €860.7m (up 3.4% from 2Q 2023). Net income: €23.9m (down 75% from 2Q 2023). Profit margin: 2.8% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Buy Or Sell Opportunity • Jul 03
Now 34% undervalued after recent price drop Over the last 90 days, the stock has fallen 40% to €210. The fair value is estimated to be €317, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Buy Or Sell Opportunity • Jul 02
Now 34% undervalued after recent price drop Over the last 90 days, the stock has fallen 39% to €213. The fair value is estimated to be €321, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Buy Or Sell Opportunity • Jul 01
Now 34% undervalued after recent price drop Over the last 90 days, the stock has fallen 42% to €213. The fair value is estimated to be €320, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Buy Or Sell Opportunity • Jun 19
Now 30% undervalued after recent price drop Over the last 90 days, the stock has fallen 43% to €212. The fair value is estimated to be €303, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Buy Or Sell Opportunity • Jun 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 34% to €242. The fair value is estimated to be €306, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Buy Or Sell Opportunity • May 29
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 32% to €240. The fair value is estimated to be €302, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Reported Earnings • Apr 18
First quarter 2024 earnings released First quarter 2024 results: Revenue: €819.6m (down 9.3% from 1Q 2023). Net income: €36.7m (down 61% from 1Q 2023). Profit margin: 4.5% (down from 10% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Upcoming Dividend • Mar 26
Upcoming dividend of €0.74 per share Eligible shareholders must have bought the stock before 02 April 2024. Payment date: 04 April 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of British dividend payers (6.1%). Lower than average of industry peers (0.6%). Declared Dividend • Feb 19
Dividend of €0.74 announced Shareholders will receive a dividend of €0.74. Ex-date: 2nd April 2024 Payment date: 4th April 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 25%. Cash payout ratio: 17%. Reported Earnings • Feb 17
Full year 2023 earnings released Full year 2023 results: Revenue: €3.40b (down 19% from FY 2022). Net income: €205.2m (down 70% from FY 2022). Profit margin: 6.0% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Aankondiging • Feb 03
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024 Buy Or Sell Opportunity • Jan 26
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 45% to €329. The fair value is estimated to be €268, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Aankondiging • Jan 18
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024 Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €257, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €231 per share. Reported Earnings • Oct 19
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: €810.7m (down 23% from 3Q 2022). Net income: €8.60m (down 94% from 3Q 2022). Profit margin: 1.1% (down from 15% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Valuation Update With 7 Day Price Move • Oct 16
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €266, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €245 per share. Aankondiging • Oct 13
Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023 SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development. Reported Earnings • Jul 26
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: €832.0m (down 20% from 2Q 2022). Net income: €95.0m (down 43% from 2Q 2022). Profit margin: 11% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €359, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €218 per share. Reported Earnings • Apr 23
First quarter 2023 earnings released First quarter 2023 results: EPS: €1.36. Revenue: €903.2m (down 12% from 1Q 2022). Net income: €93.1m (down 55% from 1Q 2022). Profit margin: 10% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Upcoming Dividend • Mar 23
Upcoming dividend of €1.44 per share at 0.4% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (0.7%). Reported Earnings • Feb 20
Full year 2022 earnings released Full year 2022 results: Revenue: €4.17b (up 21% from FY 2021). Net income: €678.1m (up 113% from FY 2021). Profit margin: 16% (up from 9.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Aankondiging • Jan 27
Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023 Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth. Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment improved over the past week After last week's 15% share price gain to €423, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 35x in the Life Sciences industry in Europe. Total returns to shareholders of 97% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €225 per share. Aankondiging • Jan 04
Sartorius Announces Management Changes for Sartorius North America Sartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment improved over the past week After last week's 17% share price gain to €391, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 120% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €191 per share. Aankondiging • Oct 20
Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023 Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023 Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment improved over the past week After last week's 15% share price gain to €402, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €241 per share. 
